Dimethandrolone (DMA, 7a, has both androgenic and progestational activities, ideal properties for a male hormonal contraceptive. In vivo, dimethandrolone undecanoate (DMAU) is hydrolyzed to DMA. We showed previously that single oral doses of DMAU powder in capsule taken with food are well tolerated and effective at suppressing both LH and testosterone (T), but absorption was low. We compared the pharmacokinetics and pharmacodynamics of two new formulations of DMAU, in castor oil and in self-emulsifying drug delivery systems (SEDDS), with the previously tested powder formulation. DMAU was dosed orally in healthy adult male volunteers at two academic medical centers. For each formulation tested in this double-blind, placebo-controlled study, 10 men received single, escalating, oral doses of DMAU (100, 200, and 400 mg) and two subjects received placebo. All doses were evaluated for both fasting and with a high fat meal. All three formulations were well tolerated without clinically significant changes in vital signs, blood counts, or serum chemistries. For all formulations, DMA and DMAU showed higher maximum (p < 0.007) and average concentrations (p < 0.002) at the 400 mg dose, compared with the 200 mg dose. The powder formulation resulted in a lower conversion of DMAU to DMA (p = 0.027) compared with both castor oil and SEDDS formulations. DMAU in SEDDS given fasting resulted in higher serum DMA and DMAU concentrations compared to the other two formulations. Serum LH and sex hormone concentrations were suppressed by all formulations of 200 and 400 mg DMAU when administered with food, but only the SEDDS formulation was effectively suppressed serum T when given fasting. We conclude that while all three formulations of oral DMAU are effective and well tolerated when administered with food, DMAU in oil and SEDDS increased conversion to DMA, and SEDDS may have some effectiveness when given fasting. These properties might be advantageous for the application of DMAU as a male contraceptive.
INTRODUCTION
Current methods of male contraception include condoms and vasectomy, both of which have drawbacks. While condoms are reversible and widely available, they have a high user failure rate. Vasectomies are efficacious, but invasive and not readily reversible. Therefore, efforts are underway to develop alternative male contraceptives with agents of known mechanisms of action. Male hormonal contraception uses exogenous sex steroids to suppress gonadotropin secretion and spermatogenesis, is reversible, and might provide additional health benefits for men if optimally designed (Liu et al., 2006; Page et al., 2008; Nieschlag, 2010; Piotrowska et al., 2016; Wang et al., 2016) . Contraceptive efficacy studies in men with weekly intramuscular (IM) injections of testosterone enanthate or monthly injections of testosterone undecanoate have been encouraging, with high efficacy rates and few side effects (World Health Organization Task Force on Methods for the Regulation of Male Fertility, 1990 ; World Health Organization Task Force on the Regulation of Male Fertility, 1996; Gu et al., 2009) . However, suppression of spermatogenesis with exogenous testosterone alone is not uniform across all ethnic groups and requires supraphysiologic dosing. By combining testosterone with a progestin, suppression of spermatogenesis is enhanced (Meriggiola & Bremner, 1997; Liu et al., 2008; Page et al., 2008; Wang & Swerdloff, 2010) . For example, the combination of testosterone implants and longacting injections of the progestin depo-medroxyprogesterone acetate has excellent contraceptive efficacy (Turner et al., 2003) . However, injections and implants may be less desirable for some men than an oral medication such as DMAU. Oral contraceptives that are user-controlled, easy to administer, and have shorter 'on and off' rates, might be desirable for many couples (Liu et al., 2006; Glasier, 2010) .
Dimethandrolone (DMA) is a novel derivative of 19-nortestosterone that binds to both the androgen and the progesterone receptors, making it an attractive candidate as a single-agent male contraceptive (Attardi et al., 2006) . DMA undecanoate (DMAU), includes a long carbon chain ester at the C-17 position (Cook & Kepler, 2005) . DMAU has been shown to be an effective, reversible contraceptive when dosed orally in pre-clinical studies. DMAU is hydrolyzed to DMA in vivo where it effectively decreases fertility in rabbits without appreciable toxicity, and is similarly non-toxic in rats and monkeys (Hild et al., 2010; Attardi et al., 2011a,b) . We previously reported the pharmacokinetics, safety, and tolerability of DMAU when given as a single oral dose as a powder in capsule to healthy male volunteers. However, we noted that this formulation resulted in low serum concentrations of DMA, likely because of the poor conversion of DMAU to DMA (about 3%) and that concomitant administration with food was required for both appreciable absorption and for conversion to DMA (Surampudi et al., 2014) . In an effort to increase the bioavailability of DMA, we reformulated oral DMAU into capsules in either castor oil or self-emulsifying drug delivery systems (SEDDS) and assessed their pharmacokinetics and pharmacodynamics when administered orally to healthy men. We hypothesized that utilization of these lipophilic drug delivery entities would enhance absorption and hydrolysis of DMAU, might negate the need for concomitant administration with food, and would optimize DMA serum concentrations for future evaluations of oral DMAU as a male hormonal contraceptive.
RESEARCH PARTICIPANTS AND METHODS

Research participants
Healthy men, age 18-50 years, with no significant medical history or illnesses, and normal physical examination, blood count, clinical chemistries, hepatitis panel, liver function tests, prostate-specific antigen (PSA) levels, electrocardiogram, and BMI <33 kg/m 2 , were included in the study. Men were excluded if they had participated in a clinical trial involving an investigational drug within 30 days, had used hormonal therapy within the last 3 months, had a disorder of the hypothalamus/pituitary/testis, desired fertility within a year, or had a pregnant partner, or had clinically significant abnormal physical or laboratory findings, or an elevated PSA. Participants were recruited and enrolled at the Harbor-UCLA Medical Center/Los Angeles Biomedical Research Institute in Torrance, California and the University of Washington in Seattle, Washington. The study protocol was approved by the institutional review boards for both participating institutions. All participants provided written informed consent prior to any study procedures. The medical monitor and the investigators reviewed adverse events and safety data weekly with the provision that an external independent data safety monitoring board be notified if and when a grade 3 adverse event occurred. 
Study medications
Study design
All participants were assessed by a study physician to ensure that all inclusion and exclusion criteria were met. For all three formulations, at each dose level evaluated, 10 men received active drug and two received placebo in a double-blind fashion. For the castor oil and SEDDS formulations, 10 participants received 100, 200, and 400 mg DMAU (for) both fasting and after a high fat meal, and two men received identical placebo capsules. One subject randomized to the DMAU in SEDDS group had no measurable DMA levels on two pharmacokinetics sampling days and his data were not included in the study (despite approval for additional procedures by the UCLA-IRB, he declined re-dosing). For the DMAU powder in capsules, participants were administered 100, 200, and 400 mg DMAU or identical placebo with a high fat meal as previously described (Surampudi et al., 2014) .
All participants were admitted to the clinical research unit within the Clinical and Translational Science Institute at each site and were observed for 24 h with hourly vital signs monitoring following dosing. An electrocardiogram was performed 4-6 and 24 h after drug administration. Safety laboratory tests (clinical chemistry panel, liver function tests) were measured at baseline and 24 h after each DMAU dose. Fasting lipids and complete blood counts were quantified at baseline, and approximately, 7 days following each dose. Serum hormones [T, free T, estradiol, dihydrotestosterone (DHT), LH, FSH, and sex hormone-binding globulin (SHBG)], were measured before drug administration (time zero) and either every 4 (castor oil and SEDDS formulations) or 12 (powder formulation) h post-administration. In all cases, DMA and DMAU concentrations were quantified in the blood drawn À0.5 before, 0, and 0.5, 1, 2, 4, 6, 8, 12, 18 , and 24 h after oral administration of DMAU. The participants returned to the clinic at least 7 days after the dose of DMAU for safety laboratory tests, adverse event reporting, vital signs, and hormone evaluation. Halting parameters for predefined safety criteria and adverse events were included in the protocol, but these parameters were never reached.
Analytical methods
Safety laboratory tests and lipid panels were performed at each institution's respective clinical laboratory. All hormones were quantified by the licensed Endocrine and Metabolic Research Laboratory at Harbor-UCLA/LA Biomed using validated methods. Serum T, DHT, estradiol, DMAU, and DMA were measured by liquid chromatography-tandem mass spectrometry (LC-MS/ MS) (Shiraishi et al., 2008; Rothman et al., 2011; Surampudi et al., 2014) and free T was calculated using a standard formula (Vermeulen et al., 1999) . Serum LH, FSH, and SHBG were measured using sensitive fluoroimmunometric assays as previously described (Swerdloff et al., 2000) .
Statistical analyses
The primary endpoints of the trial were safety and tolerability of the three formulations of DMAU. Secondary endpoints included the 24-h PK of DMAU and DMA after oral dosing fasting and with food, as well as suppression of gonadotropins and testosterone production.
The number of participants for this Phase 1 clinical study was powered to provide at least a 0.80 probability to exclude at least 20% of participants developing Grade 3 adverse events assuming a two-sided 95% confidence interval with each dose and formulation given. The PK parameters for each full sampling day for DMAU were determined by non-compartmental methods and were primarily assessed using the area under the curve from 0-24 h (AUC 0-24 ) of serum DMAU/DMA levels generated by the 10 blood sampling times over 24 h for each dose of DMAU and computed using the trapezoid method. Other PK parameters assessed included C avg (average concentration over 24 h), C max (maximum concentration over 24 h), C min (minimum concentration over 24 h), and T max (time to reach C max ). The elimination half-life, T 1/2 , was calculated assuming exponential decay when there were at least three measurable concentrations after C max .
As a dose effect is not anticipated for zero dose, the zero dose was removed from the analysis. Also, as we anticipated a marked effect of food, we planned separate analyses under the fed and fasting conditions a priori, assuming this was verified. Mixed models incorporated repeated measurements within subjects using a compound symmetrical covariance structure were constructed to examine the effect of dose (0, 200, and 400 mg), formulation (powder, SEDDS, castor oil), and the interaction on AUC, C avg , C max , T max , and T 1/2 for serum DMA, serum DMAU and the ratio of DMA to DMAU. Post hoc Bonferroni-adjusted testing was performed only when a significant main effect was detected. All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA), with two-tailed p < 0.05 construing statistical significance. Data are presented as mean AE SEM.
The effect of oral DMAU treatment on serum T, DHT, estradiol (E2), LH, FSH, and calculated free T was analyzed by mixed model analogously for C avg and C min . Models here were constructed separately using three levels of formulation (powder, SEDDS, castor oil) as well as two levels of formulation (SEDDS and castor oil), as serum concentrations for hormones were measured less frequently when the powder formulation was administered than when SEDDS and castor oil formulations were dosed. Analyses under both models yielded congruent findings, and hence, we present analyses that include all three formulations, unless otherwise indicated.
RESULTS
Research participants' demographics, disposition, and safety
There were a total of 44 participants between the two study sites, 19 for powder in capsule, 12 for castor oil, and 13 for SEDDS. A total of eight men discontinued during the dosing periods and were replaced to ensure that for all doses, 12 participants were evaluated for both fasting and fed; seven discontinued dosing during the evaluation of powder in capsule and one from SEDDS dosing. In all cases, discontinuation was because of scheduling or personal reasons and not because of adverse effects. Demographics for the participants in each phase of the study are shown in Table 1 . Across all three groups, men had an average age of 33 years and BMI of 25.
All three formulations were well tolerated and there were no serious adverse events. One participant had an AST >twofold the upper limit of normal thought to be related to binge alcohol intake; this elevation resolved without treatment. There were no significant changes in chemistry or lipid panels and hematocrit was not significantly different between baseline and the end of the study. EKGs and QTc intervals in all participants were not significantly different from baseline and there were no clinically significant changes in vital signs in any of the participants (data not shown).
Food effects
There were marked food effects on DMAU and DMA pharmacokinetics in all three formulations. When DMAU was administered with a high fat meal (50% calories as fat), DMAU absorption and DMA serum concentrations were increased leading to a significantly higher AUC, C avg , and C max for all formulations compared to administration fasting (Fig. 1 , p < 0.001 in all cases). Hence, the data were analyzed separately for the fasting and fed conditions. Pharmacokinetics of DMA and DMAU when DMAU is given with food DMA and DMAU showed higher AUC, C avg , and C max (p ≤ 0.001 for each) and DMA/DMAU AUC ratio (p = 0.044) at the 400 mg dose, compared with the 200 mg dose (2). This dose effect was true for all three formulations. Comparing the three formulations, the powder in capsule resulted in higher AUC and C max for DMAU than dosing in castor oil (p = 0.007 and p = 0.029, respectively). Despite these higher serum concentrations of DMAU, administration in powder did not increase serum DMA concentrations compared to the other two formulations. In fact, powder in capsule resulted in the lowest proportion of DMAU conversion to DMA (DMA/DMAU AUC ratio) compared with either of the other two formulations (p < 0.02 for powder in capsule compared to both castor oil and SEDDS, Table 2 ).
There was no dose effect on the time to maximum concentration, T max,, for either DMAU or DMA. However, T max for both Table 2 Comparison of PK parameters after single oral dose of DMAU in three formulations (AEstandard error of the mean). serum concentrations of DMA and DMAU were significantly delayed with powder in capsule compared with SEDDS (p < 0.05 for both DMAU and DMA). In contrast, there was an effect of dose on the elimination half-lives of DMA and DMAU (p < 0.05 for both, Table 2 ); importantly, however, the elimination halflives for both DMA and DMAU were not significantly affected by formulation.
Pharmacodynamic effects of DMAU given with food Significant dose effects were detected in C avg and C min for LH, T, free T, DHT, and E2 (p < 0.01 in all cases). Significant post hoc Bonferrroni-adjusted differences are illustrated in Fig. 2A -E, and consistently show that 400 mg was more suppressive than placebo, both in overall suppression (C avg ) and the minimum concentration achieved (C min ) ( Table 2) . A total quantity of 400 mg achieved a greater maximal suppression than 200 mg for steroids T, DHT, and E2: see Fig. 2C -E which shows the C min for each dose and formulation. There were no significant effects of the formulation on LH or any of the sex steroids examined. In contrast, there were no significant dose effects on FSH C avg , but there was a significant dose by drug interaction for FSH C min (p < 0.05, Fig. 2B ). Post hoc testing indicated that the 400 mg of SEDDS DMAU significantly suppressed FSH compared with SEDDS placebo (p = 0.004), but no other significant differences were detected. 282 Andrology, 2017, 5, 278-285 Pharmacokinetics and pharmacodynamics of DMAU administered when fasting When administered fasting, oral DMAU in the SEDDS formulation resulted in higher blood concentrations of DMAU and DMAU than the other two formulations (Fig. 1) . When the 400 mg dose was compared, these differences were significant, with SEDDS DMAU resulting in higher C avg for both DMA and DMAU than the castor oil and powder in capsule formulations (p < 0.005 for each comparison for formulation by dose interaction, Bonferroni-adjusted post hoc p < 0.03 for each comparison).
As only negligible concentrations of DMA were achieved when DMAU was administered in powder or castor oil, their pharmacodynamics effects were not further evaluated. We investigated whether DMAU given fasting in SEDDS decreased serum LH, FSH, or T in a dose-dependent manner. When given fasting, DMAU in SEDDS resulted in a dose-dependent decrease in T C avg (p = 0.0005) and C min (p = 0.015), and FSH C min (p < 0.0001) without significantly impacting LH (data not shown).
DISCUSSION
In this study, we compared the pharmacokinetics of DMAU and DMA after oral administration of single, escalating doses of three formulations of DMAU. These studies are consistent with our earlier observation that administration of DMAU with food, even when formulated in oil, markedly increases absorption (Surampudi et al., 2014) , even when formulated in oil, and result in dose incremental increases in DMAU and DMA levels. Although administering DMAU in oil did not negate the significant enhancing effect of co-administration of food on DMAU absorption, oil-based formulations improved the conversion of DMAU to DMA compared to powder in capsule. Moreover, these newer formulations of DMAU dynamically suppress LH, T, and the downstream metabolites of T, DHT, and E2, when given with food. In contrast to the powder and castor oil formulations, under fasting conditions, administration of DMAU in SEDDS provided sufficient DMA to suppress T and FSH, even after a single dose, despite resulting in markedly lower DMAU and DMA concentrations than when given with food. This study builds upon our previous work, further demonstrating that a single oral dose of DMAU of 200 or 400 mg with food significantly suppressed serum LH, T, free T, and its metabolites E 2 and DHT compared with placebo. The suppressive effect of all three formulations on sex steroids was dose dependent. The suppression of serum FSH was only evident when DMAU was given at the highest dose, 400 mg, with the SEDDS preparation, which also resulted in the highest DMA AUC (Fig 2B and Table 2 ). This is consistent with our prior observation that a single dose of DMAU as powder in capsule is a very effective suppressor of production of T, and suggests that oral DMAU may, when given repeatedly over time, be a potent suppressor of spermatogenesis (Surampudi et al., 2014) . The very rapid suppression of LH and endogenous T in response to oral DMAU may be because of the dual action of DMA on both the androgen and progesterone receptors (Attardi et al., 2006) . Combinations of androgens and progestins are more effective suppressors of spermatogenesis than T alone in male contraceptive clinical trials (Liu et al., 2008) .
We were somewhat surprised that DMAU had greater oral bioavailability when given as a powder than the other two formulations when given in the fed state ( Fig. 1 and Table 2 ), achieving greater serum DMAU C avg than the castor oil formulation. Testosterone and its short chain esters undergo rapid first-pass hepatic metabolism, limiting oral bioavailability (Tauber et al., 1986) , whereas testosterone undecanoate (TU) in castor oil has enhanced lipophilicity with absorption occurring via the intestinal lymphatics when TU is given with food (Shackleford et al., 2003) . Presumably, DMAU is also lymphatically absorbed; thus, we expected that oil emulsions would enhance absorption via this route, but this was not evident in this study. However, there was no effect of formulation on the AUC for DMA, the active metabolite of DMAU, because of the enhanced conversion of DMAU to DMA in vivo when given in either emulsified/oil formulation compared to powder (Table 2) . How administration of DMAU in oil enhances de-esterification is not clear; however, given that only 5-10% of the DMAU is metabolized to DMA systemically, the improved DMA/DMAU ratio achieved when DMAU is given in oil is likely to be a significant advantage in multiple dose studies, allowing for markedly lower amounts of DMAU to be administered to achieve equivalent pharmacodynamic effects when DMAU is given in oil/SEDDS vs. powder. This hypothesis remains to be tested in repeat dose studies as we did not observe an effect of formulation in this single dose study on the degree or extent of LH or endogenous steroid production.
Although the effects were modest, we did observe a significant effect of formulation on DMA, LH, and endogenous steroid production when DMAU was administered fasting. In particular, the SEDDS formulation was superior to both powder in capsule and the castor oil formulation in achieving significant DMA and DMAU concentrations. SEDDS has also been shown to enhance the absorption of TU (Yin et al., 2012) . While the AUC for DMAU and DMA when DMAU is administered in SEDDS is still vastly lower than when given with food, by roughly an order of magnitude (Fig. 1) , these low levels of serum DMA achieved when DMAU is given in SEDDS may be important in longer term, real use studies. As a potential contraceptive, the levels of DMA achieved with DMAU-SEDDS occasionally dosed without concomitant food, may be sufficient for maintaining gonadotropin suppression, and perhaps inhibition of spermatogenesis, in long-term daily users.
There were very few adverse events that were ascribed to DMAU. Importantly, as the studies presented here include only single doses, and involve multiple blood draws, androgenic effects such as stimulation of erythropoiesis, suppression of sex hormone-binding globulin, and potential reductions in highdensity lipoprotein cholesterol concentrations could not be adequately assessed in this study. Longer term, repeat dose studies are required to further evaluate the safety of DMAU in men. To assess the effects of DMAU on spermatogenesis as well nongonadal, androgen-sensitive organs including the prostate, bone, and muscle, longer term DMAU administration studies will be necessary. While DMAU has both androgenic and progestational activity in vitro and in pre-clinical rodent models, the long-term impact of LH and testosterone suppression on these hormonally sensitive tissues remains to be assessed and will be vital in developing DMAU as a male hormonal contraceptive.
In summary, single escalating doses of DMAU in three formulations: powder in capsule, castor oil, and SEDDS, up to 400 mg, were well tolerated in healthy male volunteers. When a single oral dose of DMAU was administered with a high fat meal, serum DMAU and DMA showed dose incremental increases sufficient to reversibly suppress LH and endogenous sex hormone production with all three formulations. Administration of DMAU in castor oil or SEDDS resulted in enhanced conversion of DMAU to DMA in vivo, which might be an advantage further development of these formulations over the powder in capsule. Furthermore, DMAU given in SEDDS was superior to the other two formulations when given in the fasting state, resulting in higher serum DMA concentrations sufficient for suppression of T and FSH. Further development of oral DMAU is ongoing with the goal of assessing its safety and efficacy in suppressing endogenous gonadotropins, sex steroids, and, in the long run, sperm production. These studies demonstrate that the formulation of DMAU in oil may have some advantages over powder in capsule; whether these observations hold true with multiple, repeat dosing remains to be evaluated. DMAU holds promise as a potential single agent, reversible, male hormonal contraceptive.
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